The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century.
Despite widespread pneumococcal vaccination of children and adults, invasive pneumococcal disease (IPD) remains prominent. Using our database of all Streptococcus pneumoniae infections at the Veterans Affairs Medical Center, Houston, Texas, since 2000, we reviewed cases of IPD, defined as the isolation of pneumococci from any normally sterile body site. In 136 cases, the mean age of patients was 63 years; 43% were African American, a higher proportion than the 30% served by our hospital. One hundred sixteen patients (85%) had pneumonia, of whom 3 also had empyema. Seven had bacteremia with no apparent source, 5 meningitis, 5 spontaneous bacterial peritonitis, 3 septic arthritis, 2 endocarditis, and individual patients had osteomyelitis and/or localized abscesses. One hundred twenty-one patients (89%) had > or =1 underlying condition associated with susceptibility to pneumococcal infection, and another 8 (6%) were aged >65 years old. Thus only 5% of patients lacked a condition for which 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended. Fifty-five percent had been vaccinated; similar proportions of vaccine serotypes infected previously vaccinated and nonvaccinated patients. All but 2 isolates were fully susceptible to penicillin and cefotaxime as currently defined. Consistent with substantial replacement of infecting serotypes since the introduction of 7-valent pneumococcal conjugate vaccine (PCV7), none of the predominant infecting serotypes was included in PCV7, although all except for 6A were contained in PPV23. The overall mortality at 30 days was 16% and was similar in vaccinated and nonvaccinated subjects. IPD causes a wide spectrum of disease. Mortality is substantial. PPV23 is clearly not fully protective.
Rueda
Adriana M
AM
From the Medical Service (Infectious Disease Section), Michael E. DeBakey Veterans Affairs Medical Center (AMR, M Matloobi, M Mushtaq, DMM), Houston; and the Departments of Medicine (AMR, JAS, DMM), and Molecular Virology and Microbiology (DMM), Baylor College of Medicine, Houston, Texas.
Serpa
José A
JA
Matloobi
Mahsa
M
Mushtaq
Mahwish
M
Musher
Daniel M
DM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003710:Demography; D006760:Hospitalization / Q000639:trends*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000382:microbiology* / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D015995:Prevalence; D012720:Severity of Illness Index; D055512:Tertiary Prevention / Q000639:trends*; D013997:Time Factors; D014611:Vaccination / Q000706:statistics & numerical data
D022242:Pneumococcal Vaccines
Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1569-1576.
Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Linares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother. 2009;64:507-510.
Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60:759-776.
Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3:e168.
Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis. 1985;7:133-142.
Dudley S, Ashe K, Winther B, Hendley JO. Bacterial pathogens of otitis media and sinusitis: detection in the nasopharynx with selective agar media. J Lab Clin Med. 2001;138:338-342.
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223-229.
Glover DT, Hollingshead SK, Briles DE. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun. 2008;76:2767-2776.
Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, Patterson S, van Alphen AJ, Bonten MJ. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66:378-383.
Harrison LH, Dwyer DM, Billmann L, Kolczak MS, Schuchat A. Invasive pneumococcal infection in Baltimore, Md: implications for immunization policy. Arch Intern Med. 2000;160:89-94.
Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-1354.
Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, Schouls LM, Sanders EA, van der Ende A. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27:2394-2401.
Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006;5:651-667.
Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. 2009;49:205-212.
Klemets P, Lyytikainen O, Ruutu P, Ollgren J, Pekka Nuorti J. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis. 2008;8:96.
Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis. 2002;2:721-736.
Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. 1980;69:507-512.
Lippmann ML, Goldberg SK, Walkenstein MD, Herring W, Gordon M. Bacteremic pneumococcal pneumonia. A community hospital experience. Chest. 1995;108:1608-1613.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-S72.
Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;(1):CD000422.
Motlova J, Benes C, Kriz P. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006. Epidemiol Infect. 2009;137:562-569.
Mufson MA, Oley G, Hughey D. Pneumococcal disease in a medium-sized community in the United States. JAMA. 1982;248:1486-1489.
Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, Inderias LA, Phan HM, Solomon E. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore). 2000;79:210-221.
Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med. 2001;161:2538-2544.
Musher DM, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis. 1990;161:728-735.
Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201:516-524.
Musher DM, Phan HM, Watson DA, Baughn RE. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia. J Infect Dis. 2000;182:158-167.
Orihuela CJ, Mahdavi J, Thornton J, Mann B, Wooldridge KG, Abouseada N, Oldfield NJ, Self T, Ala'Aldeen DA, Tuomanen EI. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest. 2009;119:1638-1646.
Ort S, Ryan JL, Barden G, D'Esopo N. Pneumococcal pneumonia in hospitalized patients. Clinical and radiological presentations. JAMA. 1983;249:214-218.
Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006;44:124-131.
Park JY, Choi HJ, Prabagar MG, Choi WS, Kim SJ, Cheong C, Park CG, Chin CY, Kang YS. The C-type lectin CD209b is expressed on microglia and it mediates the uptake of capsular polysaccharides of Streptococcus pneumoniae. Neurosci Lett. 2009;450:246-251.
Raz R, Elhanan G, Shimoni Z, Kitzes R, Rudnicki C, Igra Y, Yinnon A. Pneumococcal bacteremia in hospitalized Israeli adults: epidemiology and resistance to penicillin. Clin Infect Dis. 1997;24:1164-1168.
Ridda I, Macintyre CR, Lindley R, Gao Z, Sullivan JS, Yuan FF, McIntyre PB. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. 2009;27:1628-1636.
Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, Plikaytis BD, Carlone GM. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29:281-288.
Ross JJ, Saltzman CL, Carling P, Shapiro DS. Pneumococcal septic arthritis: review of 190 cases. Clin Infect Dis. 2003;36:319-327.
Tsigrelis C, Tleyjeh IM, Lahr BD, Nyre LM, Virk A, Baddour LM. Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007: a population-based study. Clin Infect Dis. 2008;47:1367-1371.
Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37:230-237.